A randomized, intraindividual, non‐inferiority, Phase <scp>III</scp> study comparing daylight photodynamic therapy with <scp>BF</scp>‐200 <scp>ALA</scp> gel and <scp>MAL</scp> cream for the treatment of actinic keratosis

Abstract

Daylight PDT of AK with BF-200 ALA is well-tolerated and non-inferior to MAL/dPDT. The study demonstrates a trend towards higher efficacies after 3 months and significantly lower recurrence rates after 1 year follow-up.